Latest News by Industry
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug 29, 2024--
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will be presenting at the following investor conferences:
Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera's Investor Relations website. Replays of each webcast will be available through the same links following the presentations.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20240829861441/en/
CONTACT: InquiriesMedia: Kathleen Reid;media@abcellera.com, +1(236)521-6774
Business Development: Murray McCutcheon, Ph.D.;bd@abcellera.com, +1(604)559-9005
Investor Relations: Melanie Solomon;ir@abcellera.com, +1(778)729-9116
KEYWORD: NEW YORK MASSACHUSETTS UNITED STATES NORTH AMERICA CANADA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY
SOURCE: AbCellera Biologics Inc.
Copyright Business Wire 2024.
PUB: 08/29/2024 04:05 PM/DISC: 08/29/2024 04:06 PM
http://www.businesswire.com/news/home/20240829861441/en